Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Regenity Biosciences Completes 1st Surgery with RejuvaKnee - Orthopedic Design & Technology
OEM News

Regenity Biosciences Completes 1st Surgery with RejuvaKnee

RejuvaKnee is FDA-approved and designed to facilitate the regeneration of native meniscal tissue, enabling a more complete recovery as compared to removing or replacing the meniscus.

Regenity Biosciences’ RejuvaKnee device.

Regenity Biosciences announced the successful completion of the first surgery using RejuvaKnee, its collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus.

Paul Fleissner, MD, an orthopedic surgeon at the Crystal Clinic in Akron, OH, performed the surgery utilizing the RejuvaKnee implant to treat a college-aged athlete suffering from chronic pain following a prior meniscectomy.

The RejuvaKnee implant is FDA-cleared as a regenerative implant device for meniscal repair. It is designed to facilitate the regeneration of native meniscal tissue, enabling a more complete recovery as compared to removing or replacing the meniscus. 

“I believe the RejuvaKnee implant has the potential to be a game-changer for meniscal restoration, especially for younger patients under forty seeking the most durable procedure,” said Dr. Fleissner. “The device offers excellent handling properties, is user-friendly for surgeons, and serves as a convenient ‘off-the-shelf’ solution for those who have irreparable tears or have previously lost meniscal tissue.”

In a 12-month animal study, the implant demonstrated the ability to regenerate meniscal tissue that withstands full weight-bearing within three months, restoring the knee’s normal range of motion.1

“The first surgery using RejuvaKnee is another meaningful milestone for Regenity, highlighting our mission to improve patient outcomes through regenerative medicine,” said Shawn McCarthy, CEO of Regenity Biosciences. “With RejuvaKnee, we’re helping patients restore quality of life through tissue regeneration. This innovation underscores our leadership commitment to advancing next-generation solutions in Sports Medicine and making what should be a patient’s first surgery last.”

References:

1 Regenity Data on File, 2024

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters